There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TRAIL R2


Brief Information

Name:Tumor necrosis factor receptor superfamily member 10B
Target Synonym:Tumor necrosis factor receptor superfamily member 10B,CD262,DR5,KILLER,TRAILR2,Death receptor 5,TRAIL-R2,UNQ160/PRO186,TNFRSF10B,TNF Receptor Superfamily Member 10b,TNF-Related Apoptosis-Inducing Ligand Receptor 2,TRICK2,ZTNFR9,P53-Regulated DNA Damage-In
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:10
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

Part of Bioactivity data


Loaded Human TRAIL R2, Fc Tag (Cat. No. TR2-H5255) on AHC Biosensor, can bind Human TRAIL, His Tag with an affinity constant of 0.146 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Mouse TRAIL R2, His TagMouse TRAIL R2, His Tag (Cat. No. TR2-M52H5) ELISA bioactivity

Immobilized Human TNFSF10 at 2 μg/mL (100 μL/well) can bind Mouse TRAIL R2, His Tag (Cat. No. TR2-M52H5) with a linear range of 0.039-0.625 μg/mL (QC tested).

Synonym Name



Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) is also known as TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2), Death receptor 5 (DR5), CD262, KILLER, is a member of the TNF-receptor superfamily, and contains an intracellular death domain.  TNFRSF10B / DR-5 is widely expressed in adult and fetal tissues; very highly expressed in tumor cell lines. TRAILR2 / CD262 / DR5 is the receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD (a death domain containing adaptor protein) of TRAIL-R2 / TNFRSF10B recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. CD262 / DR5 Promotes the activation of NF-kappa-B. DR5 is essential for ER stress-induced apoptosis and is regulated by p53/TP53.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Anti-DR5 CAR-T cell therapy (Shenzhen BinDeBio) Phase 2 Clinical Shenzhen Binder Biotechnology Co Ltd Liver Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Glioma; Carcinoma, Hepatocellular Details
JCT-205 JCT-205 Phase 1 Clinical Inhibrx Adenocarcinoma Details
Eftozanermin alfa APG-350; APG-880; ABBV-621; PR-1625011 Phase 1 Clinical Abbvie Inc Hematologic Neoplasms; Multiple Myeloma Details
GEN-1029 iDD-004; GEN-1029; Hx-DR5-01; Hx-DR5-05 Phase 2 Clinical Idd Biotech Stomach Neoplasms; Carcinoma; Carcinoma, Renal Cell; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Recombinant human tumor necrosis factor-related apoptosis-inducing ligand (Shenzhen Xinpeng Biotech) Phase 3 Clinical Shenzhen Xinpeng Biology Engineering Co Ltd Neoplasms Details
Conatumumab AMG-655 Phase 2 Clinical Amgen Inc Ovarian Neoplasms; Solid tumours; Carcinoid Tumor; Rectal Neoplasms; Carcinoma, Ovarian Epithelial; Colonic Neoplasms; Pancreatic Neoplasms; Sarcoma; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Lymphoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis Details
Circularly permuted TRAIL (Beijing Sunbio Biotech) Phase 3 Clinical Beijing Shadong Biotech Co Ltd Multiple Myeloma Details
Recombinant anti-human DR5 monoclonal antibody (Lonn Ryonn Pharma) CTB-006 Phase 1 Clinical Beijing Tongwei Shidai Shengwu Jishu Youxian Gongsi, Lonn Ryonn Pharma Ltd Solid tumours Details
Dulanermin (Shanghai GeBaiDe) Phase 3 Clinical Shanghai Gebaide Biotechnology Co Ltd Carcinoma, Non-Small-Cell Lung Details
BI-905711 BI-905711 Phase 1 Clinical Boehringer Ingelheim Gmbh Pancreatic Neoplasms; Cholangiocarcinoma; Gastrointestinal Neoplasms Details
Oba-01 Oba-01; Oba01 Phase 1 Clinical Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.